general
- Generic Name : Ibalizumab-uiyk
- Pronunciation : eye-ba-LIZ-ue-mab-uiyk
- Therapeutic Classification : Monoclonal antibodies
- Trade Name : Trogarzo
prescription
Ibalizumab-uiyk intravenous injection is prescribed in conjunction with other antiretroviral medications for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults. It is indicated for HIV patients who have:
- A previous history of antiretroviral therapies
- Multidrug-resistant HIV-1 infection
- Experienced failure or loss of response with other antiretroviral medicines
Ibalizumab-uiyk functions as a post-attachment inhibitor by binding to the CD4 glycoprotein, the primary receptor for the human immunodeficiency virus. This action blocks the viral entry process into immune cells.
risk factors
Ibalizumab-uiyk is not advisable in patients who:
- Have an allergy to ibalizumab-uiyk
- Are pregnant or breastfeeding
- Are under 18 years of age
side effects
- Nausea
- Diarrhea
- Dizziness
- Skin rashes (erythematous, maculopapular, or generalized)
- Alterations in the immune system
dosage
- The suggested dosage for ibalizumab-uiyk involves an initial single loading dose of 2000 mg, followed by a maintenance dose of 800 mg administered every two weeks.
- No dose modification is required when concurrently using other antiretroviral medications or undergoing additional treatments.
how to take
- Ibalizumab-uiyk is provided as an injection and should be administered by a trained healthcare provider directly into the vein as a slow infusion lasting approximately 15 to 30 minutes.
- Ibalizumab-uiyk must only be diluted with 250 ml of 0.9% sodium chloride injection and should be administered within 4 hours if stored at room temperature (below 25°C) or within 24 hours if stored in a refrigerator (2°C to 8°C).
- The refrigerated solution should be allowed to reach room temperature for at least 30 minutes before administration.
- Following the completion of each ibalizumab-uiyk infusion, it is advisable to flush the medication with 30 ml of 0.9% sodium chloride.
- Any unused or partially used vials of ibalizumab-uiyk should be discarded.
warning
- Patients should undergo monitoring for the potential risk of immune reconstitution inflammatory syndrome, necessitating additional assessment and supportive treatment.
- Regular monitoring of patients for laboratory abnormalities is essential to identify fluctuations in blood sugar levels and various markers for blood disorders.
- Evaluation of bilirubin, creatinine, and uric acid levels is also recommended during ibalizumab-uiyk treatment.
storage
2°C to 8°C